Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224279 | 1.00 | KCNH2 (0.47) | KCNH2SIGMAR1CLK1 | |
| SCHEMBL1222537 | 1.00 | KCNH2 (0.47) | KCNH2SIGMAR1CLK1 | |
| SCHEMBL1222627 | 0.86 | SIGMAR1 (0.49) | KCNH2SIGMAR1 | |
| SCHEMBL1222641 | 0.86 | SIGMAR1 (0.49) | KCNH2SIGMAR1 | |
| SCHEMBL1222631 | 0.86 | SIGMAR1 (0.49) | KCNH2SIGMAR1 | |
| SCHEMBL1224142 | 0.84 | SIGMAR1 (0.47) | KCNH2SIGMAR1 | |
| SCHEMBL1224148 | 0.84 | SIGMAR1 (0.47) | KCNH2SIGMAR1 | |
| SCHEMBL1224294 | 0.84 | KCNH2 (0.44) | KCNH2SIGMAR1CLK1 | |
| SCHEMBL1223989 | 0.83 | KCNH2 (0.47) | KCNH2SIGMAR1CLK1 | |
| SCHEMBL1223982 | 0.83 | KCNH2 (0.47) | KCNH2SIGMAR1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
| EP-2144910-A2 | OXAZOLIDINONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | KCNH2 912/4885SIGMAR1 364/4885CLK1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.